RARECast

Patients, long passive participants in the drug research and development process, are playing a more active role, and the value of their input is being recognized by researchers, drugmakers, and regulators. The 21st Century Cures Act, sweeping legislation now pending in Congress, would help solidify that role by providing opportunities for patient input into the regulatory process. We spoke to Kim...

Fibrocell Science is developing cell and gene therapy to treat rare skin and connective tissue diseases. The company recently reported encouraging pre-clinical results on its gene therapy for RDEB a congenital, progressive, and debilitating genetic disorder that leads to death. The data sets the stage for Fibrocell and its partner Intrexon to advance the experimental therapy to human clinical tria...

Patent filings in the area of rare diseases suggest government incentives have worked to spur innovation, according to a new report from the international intellectual property firm Marks & Clerk. The report examines patent filings in the areas of rare diseases, antibiotics, and vaccines. We spoke to Gareth Williams, partner and European patent attorney with Marks & Clerk, about the report, the ro...

Disruptive changes to the healthcare landscape are creating new tensions in the traditional relationship between pharmaceutical companies and patient advocacy groups, according to the findings of a report from InVentiv Health. The report, based on interviews with nearly four dozen representatives of patient advocacy organizations, finds patient advocates expect greater transparency from their phar...

Bellus Health was originally formed around technology seen as the basis for promising therapeutics for Alzheimer’s disease, but the company also pursued rare disease opportunities as well. Despite encouraging results, the financial crisis made it difficult for the company to advance its potential Alzheimer’s therapy. With a new CEO put in place, the company overhauled its strategy, out licensed it...

The Lion’s Mouth Opens, Lucy Walker’s critically acclaimed short documentary, begins at a dinner between the actress and filmmaker Marianna Palka and her friends the night before she gets results from a genetic test that will tell her whether she carries the gene for Huntington’s disease. Palka’s father has had a long battle with the neurodegenerative disorder and she has a 50 percent chance of ha...

Royal Pains, the television program about a concierge doctor in the Hamptons, begins its seventh season on the USA Network June 2. As the new season begins, the shows is expected to take an increased focus on rare diseases as the mysterious billionaire Boris Kuester von Jurgens-Ratenicz has decided to fund a rare disease research center. We spoke to Royal Pains Executive Producer Michael Rauch, Ex...

Nick Sireau’s efforts to find a cure for his children’s rare genetic disease alkaptonuria caused him to confront struggles faced by many people within the rare disease community as they seek to raise funds, foster research, and learn about running clinical trials and supporting patients. The experience led him to create Findacure, an organization that seeks to train, mentor, and empower patient gr...

MPS I is a rare genetic disease that is incurable and lethal by age 12. Seattle-base Immusoft thinks it can harness a key part of the immune system to manufacture a missing enzyme needed to treat the disease. It represents a broader effort on the part of the company to develop a platform to treat a wide range of disease by turning immune system cells into drug factories. We spoke to Matthew Scholz...

The legendary Notre Dame football coach Ara Parseghian lost three of his grandchildren to Niemann-Pick Type C, a rare and fatal genetic disease. Parseghian’s story has helped mobilize members of the Notre Dame community, and in particular, Greg Crawford, Dean of the College of Science and professor of physics, in a fight against the disease. Crawford has been named a finalist in the Biotechnology...

Last month Utah Governor Gary Herbert signed into law the Right to Try Act, which provides terminally ill patients access to experimental drugs that have completed at least early-stage clinical testing. Utah is the tenth state to pass such law and a growing list of other states are considering similar legislation. We spoke to Jonathan Johnson, founder of Utah’s Right to Try Foundation, about the l...

When a doctor delivered a devastating diagnosis to Pat Furlong for her two sons with Duchenne Muscular Dystrophy, she refused to sit by and just watch them slowly die. She marched off to Washington to corner her Senator and the director of the National Institutes of Health, borrowed money to fund her sudden role as a patient advocate, and brought together academic researchers to get them thinking...

Lysosomal storage disorders are a group of genetic rare diseases that can manifest themselves in a diverse set of symptoms and can be difficult to diagnose. Now Courtagen Life Sciences has brought to market LysoSEEK, a next-generation genetic tests for sequencing 94 genes associated with nearly 60 metabolic disorders. The new test provides an alternative to the piecemeal testing that can provide a...

David Pearce created the Coordination of Rare Diseases at Sanford or CoRDS registry as a national resource that could help accelerate research into rare diseases. We spoke to Pearce, president of Sanford Research, director of Sanford Children’s Health Research Center, and the Global Genes 2012 Champions of Hope honoree for Research & Science, about his own research into the neurodegenerative disor...

Carri Levy’s search to find answers to her daughter’s lifelong illness was made worse by doctors that insisted there was no problem. A producer for the daily morning show The Balancing Act on Lifetime TV, Levy launched the series Behind the Mystery: Rare and Genetic, in effort to search for answers to her daughter’s illness. As part of a series of podcasts revisiting past winners of Global Genes’...

As a child, Sami Petersen developed progressive scoliosis, a severe curvature of the spine as a result of a rare genetic disease. The condition eventually led to complex spinal surgery to correct the worsening deformity, pain, and complications. As she recovered from her operation, Petersen, who was 15 at the time, decided to launch the organization SHIFT Scoliosis, which has grown from a small aw...

The U.S. Food and Drug Administration approved more than 230 new drugs to treat rare diseases in the past decade and there are currently more than 450 orphan drugs in development, according to a new report (http://onphr.ma/1EsGJw6) from the Pharmaceutical Research and Manufacturers of America. Though developing drugs for rare diseases presents many challenges, policy changes and scientific breakth...

Though there are almost 7,000 rare diseases, less than 500 drugs have been approved to treat any one of them. What that means for millions of people with a rare disease is that there’s no approved treatment they can use. There is, however, a growing effort to look at drugs approved for other uses and repurpose them to treat rare diseases in which they might be effective. We spoke to Julia Jenkins,...

Recursion Pharmaceuticals has set the audacious goal for itself of developing 100 drugs in 10 years for rare diseases. The company, focused on repurposing compounds abandoned in clinical development by other drugmakers, thinks it can achieve this by a fundamentally different approach to drug development than the industry’s traditional process of screening compounds against potential disease target...

Noah Coughlan will set out on a 3,100 mile run across America from the Statue of Liberty to San Diego’s Ocean Beach in the hope of raising awareness and support in the fight against rare diseases. It will be the third run across the country for the founder of the Run4Rare Foundation and begin on February 28, World Rare Disease Day. We spoke to Coughlan about his run, what motivated him to do this,...

The search for cures for diseases is limited by the ability of scientists to consume and understand the rapidly expanding volumes of biomedical literature produced each year. Andrew Su, associate professor in the department of Molecular and Experimental Medicine at The Scripps Research Institute, has a solution. He wants to enlist members of the rare disease community and general public to become...

World Rare Disease Day, an annual observance held on the last day of February, seeks to raise awareness for rare diseases. On that day, hundreds of patient organizations from more than 80 countries will be participating in activities to call attention to thousands of ailments, many of which are without treatments or even names. We spoke to Hudson Freeze, director of the Human Genetics Program at S...

At the age of 8, Bill Elder, Jr. was diagnosed with cystic fibrosis, a rare, genetic disease expected to cut his life short. Now a third year medical student, Elder has been the beneficiary of Vertex Pharmaceutical’s Kalydeco, an example of the transformative effects personalized therapies can have on patients. As President Barack Obama announced plans for a precision medicine initiative during hi...

The combination of high cost, long development times, and small patient populations for rare diseases is driving new models to accelerate drug development. The story of the newly formed rare disease company Vtesse is a compelling example. Driven by parents, advanced to the clinic by the National Institutes of Health, and licensed by a new company formed out of an orphan drug accelerator, Vtesse is...

Crowdfunding, once thought of as little more than a way to raise money for small scientific projects, is increasingly being used to raise significant capital to fund startups. Perlstein Lab, a San Francisco-based starup focused on finding new drugs to treat rare diseases, raised more than $2 million using crowdfunding. We spoke to Ethan Perlstein, founder and CEO of Perlstein Lab, about his compan...